187 related articles for article (PubMed ID: 21853037)
1. Serum methionine metabolites are risk factors for metastatic prostate cancer progression.
Stabler S; Koyama T; Zhao Z; Martinez-Ferrer M; Allen RH; Luka Z; Loukachevitch LV; Clark PE; Wagner C; Bhowmick NA
PLoS One; 2011; 6(8):e22486. PubMed ID: 21853037
[TBL] [Abstract][Full Text] [Related]
2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
3. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
4. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy.
Blum DL; Koyama T; M'Koma AE; Iturregui JM; Martinez-Ferrer M; Uwamariya C; Smith JA; Clark PE; Bhowmick NA
Clin Cancer Res; 2008 Dec; 14(23):7790-7. PubMed ID: 19047106
[TBL] [Abstract][Full Text] [Related]
5. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.
Erho N; Crisan A; Vergara IA; Mitra AP; Ghadessi M; Buerki C; Bergstralh EJ; Kollmeyer T; Fink S; Haddad Z; Zimmermann B; Sierocinski T; Ballman KV; Triche TJ; Black PC; Karnes RJ; Klee G; Davicioni E; Jenkins RB
PLoS One; 2013; 8(6):e66855. PubMed ID: 23826159
[TBL] [Abstract][Full Text] [Related]
6. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
Nelson CP; Dunn RL; Wei JT; Rubin MA; Montie JE; Sanda MG
Urol Oncol; 2003; 21(3):213-8. PubMed ID: 12810209
[TBL] [Abstract][Full Text] [Related]
7. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
8. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
J Urol; 2002 Feb; 167(2 Pt 1):516-20. PubMed ID: 11792909
[TBL] [Abstract][Full Text] [Related]
9. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
10. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer.
Grossfeld GD; Latini DM; Lubeck DP; Mehta SS; Carroll PR
J Urol; 2003 Jan; 169(1):157-63. PubMed ID: 12478126
[TBL] [Abstract][Full Text] [Related]
11. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
Antonarakis ES; Feng Z; Trock BJ; Humphreys EB; Carducci MA; Partin AW; Walsh PC; Eisenberger MA
BJU Int; 2012 Jan; 109(1):32-9. PubMed ID: 21777360
[TBL] [Abstract][Full Text] [Related]
12. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191
[TBL] [Abstract][Full Text] [Related]
13. Natural history of progression after PSA elevation following radical prostatectomy.
Pound CR; Partin AW; Eisenberger MA; Chan DW; Pearson JD; Walsh PC
JAMA; 1999 May; 281(17):1591-7. PubMed ID: 10235151
[TBL] [Abstract][Full Text] [Related]
14. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
[TBL] [Abstract][Full Text] [Related]
15. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
JAMA; 2005 Jul; 294(4):433-9. PubMed ID: 16046649
[TBL] [Abstract][Full Text] [Related]
16. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
17. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
[TBL] [Abstract][Full Text] [Related]
18. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
19. Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S.
Pan J; Shao X; Zhu Y; Dong B; Wang Y; Kang X; Chen N; Chen Z; Liu S; Xue W
Int J Nanomedicine; 2019; 14():431-440. PubMed ID: 30666105
[TBL] [Abstract][Full Text] [Related]
20. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
